

PB 39 of 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2025

I, Rebecca Richrdson, as delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 16 April 2025

Rebecca Richardson
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care



Conte	ents	
	1 Name	
	2 Commencement	
	3 Authority	
	4 Schedules	
Schedul	e 1—Amendments—General	2
	National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023	, 2
Schedul	e 2—Amendments— Additional designated brands effective from 1 October 2025	3
	National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023	<u>:</u>



1 Name

- (1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2025.
- (2) This instrument may also be cited as PB 39 of 2025.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information				
Column 1	Column 2	Column 3		
Provisions	Commencement	Date/Details		
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	The day after this instrument is registered.			
2. Schedule 1	The day after this instrument is registered.			
3. Schedule 2	1 October 2025.	1 October 2025		

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99ADHC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—General

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1 Section 5 (table)

Omit:

Estradiol Transdermal Estradiol System (Sandoz, USA)

Transdermal patches 1.17 mg, 8

Transdermal

Schedule 2—Amendments— Additional designated brands effective from 1 October 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1 Section 5 (after table item dealing with the brand Largactil of the drug Chlorpromazine in the form Tablet containing chlorpromazine hydrochloride 25 mg)

Insert:

Ovidrel Choriogonadotropin

alfa

Solution for injection 250 micrograms in 0.5 mL pre-filled

Injection

pen

2 Section 5 (after table item dealing with the brand Estalis continuous 50/140 of the drug Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8)

Rosuzet Composite Pack	Ezetimibe and rosuvastatin	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)	Oral
Rosuzet Composite Pack	Ezetimibe and rosuvastatin	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)	Oral
Rosuzet Composite Pack	Ezetimibe and rosuvastatin	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium)	Oral
Rosuzet Composite Pack	Ezetimibe and rosuvastatin	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)	Oral

3 Section 5 (after table item dealing with the brand Levetiracetam Viatris of the drug Levetiracetam in the form Tablet 1 g)

Insert:

WGR

LEVETIRACETAM-

Levetiracetam

Tablet 1 g

Oral

4 Section 5 (after table item dealing with the brand NOUMED LEVETIRACETAM of the drug Levetiracetam in the form Tablet 1 g)

Insert:

Mirena Levonorgestrel

Intrauterine drug delivery system

Intrauterine

52 mg

5 Section 5 (after table item dealing with the brand Penthrox (Combination Pack) of the drug Methoxyflurane in the form Liquid for inhalation 999 mg per g, 3 ml (with inhaler))

Insert:

Artige	Methylphenidate	Tablet containing methylphenidate hydrochloride 10 mg	Oral
Ritalin 10	Methylphenidate	Tablet containing methylphenidate hydrochloride 10 mg	Oral

6 Section 5 (after table item dealing with the brand Ordine 5 of the drug Morphine in the form Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 1 mL)

Insert:

moere.			
Prenoxad	Naloxone	Injection containing naloxone hydrochloride 2 mg in 2 mL prefilled syringe	Injection
Nyxoid	Naloxone	Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2	Nasal
Naprosyn SR1000	Naproxen	Tablet 1 g (sustained release)	Oral
Proxen SR 1000	Naproxen	Tablet 1 g (sustained release)	Oral
Naprosyn	Naproxen	Tablet 250 mg	Oral
Naprosyn SR750	Naproxen	Tablet 750 mg (sustained release)	Oral
Proxen SR 750	Naproxen	Tablet 750 mg (sustained release)	Oral
Anaprox 550	Naproxen	Tablet containing naproxen sodium 550 mg	Oral
Crysanal	Naproxen	Tablet containing naproxen sodium 550 mg	Oral

7 Section 5 (after table item dealing with the brand Micolette of the drug Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate in the form Enemas 3.125 g-450 mg-45 mg in 5 mL, 12)

Insert:

TENOFOVIR/EMTRICITABINE 300/200 ARX	Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral
Timoptol XE	Timolol	Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL	Application to the Eye
Timoptol	Timolol	Eye drops 5 mg (as maleate) per mL, 5 mL	Application to the Eye

8 Section 5 (after table item dealing with the brand Lipistart of the drug Triglycerides - medium chain, formula in the form Oral powder 400 g (Lipistart))

Insert:

ProZero Triglycerides, long Oral liquid 1 L, 6 (ProZero) Oral

chain with glucose

polymer